Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.

Advancements in artificial intelligence, precision medicine, and digital health pave the way for innovation that enhances patient care, improves efficiency, and addresses evolving regulatory and ...